Panaxia in collaboration with Rafa, the Israeli Pharmaceutical company, has begun a clinical trial for registration at the Ministry of Health, intended to make medical cannabis accessible to a wide range of patients asking to receive the treatment in a conventional pharmaceutical way other than smoking, in order to ensure an accurate and consistent treatment dosage.
LOD, Israel, April 23, 2019 /CNW/ -- The pharmaceutical company Panaxia Israel Pharmaceutical Industries, announced a clinical trial for registration purposes at the Ministry of Health, a first of its kind process, for delivering sublingual tablets of medical cannabis to examine their bioavailability and safe consumption. Panaxia's medical cannabis products, distributed by the pharmaceutical company Rafa, are being tested as part of a clinical trial, and their registration following the trial will revolutionize medical cannabis treatment. The greatest potential in tablets which are taken sublingually, is mainly for patients suffering from chronic/persistent pain.
As of November 2018, chronic neuropathic pain is considered the most common medical condition in over 42,000 patients with permits for medical cannabis treatment. "In extended chronic pain, there is a significant advantage for treatments with a relatively immediate response and a longer effect period," says Dr. Silviu Brill, Director of the Chronic and Acute Pain Center, at the Tel-Aviv Sourasky Medical Center, and Honorary Treasurer at the European Pain Federation. "This is why, medical cannabis sublingual tablets, which are based on clinical trials, are so significant in treating patients suffering from chronic pain. Tablets are a convenient, simple and familiar method of treatment administration for patients suffering from chronic pains, and will enable us physicians to better manage the treatment of pain with medical cannabis."
Sublingual tablets are adapted for treating most patients. 80% of the adult population in Israel are non-smokers, which is why this is good news for many patients which are unwilling or unable to smoke.
According to Dr. Dadi Segal, Panaxia CEO, "The clinical trial is performed as part of the registration process of the new products which we are planning to launch in Israel, in collaboration with Rafa, this year. By making medical cannabis accessible through tablets, we strive to provide treatment with medical cannabis products for patients with a wide range of diseases, after completing the trial and registration, and subject to recommendation by a medical specialist. Firstly, the new method of administration will enable patients to receive the treatment with no smoking damages."
Anat Savion, Rafa CEO, adds, "As a veteran pharmaceutical company operating for years in the field of pain treatment and Palliative treatment, we see great significance in developing pharmaceutical administration methods for medical cannabis. The new development of medical cannabis tablets will enable a precise and consistent adjustment of the treatment for patients."
About Panaxia Israel
Panaxia Israel (www.panaxia.co.il) is part of the pharmaceutical group of the Segal family, operating for over four decades, and manufacturing over 600 different pharmaceutical products, which it distributes in over 30 countries. Panaxia was founded by Dr. Dadi Segal, Dr.Eran Goldberg and Assi Rotbart, LL.b, and constitutes the Group's cannabis division. In addition, the sister-division of North America manufactures over 60 pharmaceutical products based on medical cannabis, including sublingual tablets, oral tablets, oils, inhalers, and more, intended to treat conditions such as post-traumatic stress, cancer, chronic pains, epilepsy, anorexia, burns, and many other medical conditions. Panaxia employs around 90 employees and all clinical experiments are conducted by the company.
For further info: Steve Levy, Email – firstname.lastname@example.org/ Tel (305) 933-4646
SOURCE Panaxia Pharmaceutical Industries